Endothelial ACKR1 expression regulates neutrophil infiltration and breast cancer metastatic engraftment in the lung metastatic niche

This study demonstrates that primary breast tumors upregulate endothelial ACKR1 in the lung premetastatic niche to recruit neutrophils, thereby facilitating tumor cell engraftment and metastasis.

The Gist

The Big Picture: How Cancer Finds a "Home" in the Lungs

Imagine your body is a bustling city. Breast cancer is like a group of troublemakers who have escaped their original neighborhood (the breast) and are trying to sneak into other parts of the city to start new, dangerous settlements.

One of their favorite places to move is the lungs. But the lungs aren't just empty rooms waiting to be filled; they are guarded fortresses. For the cancer to succeed, it needs to trick the lung's security system into opening the gates and building a welcoming committee.

This paper discovers a specific "security guard" on the blood vessels in the lungs that the cancer tricks into helping them. This guard is called ACKR1.

---

The Story in Three Acts

Act 1: The Signal from the Primary Crime Scene

When a breast tumor grows, it doesn't just sit there. It sends out secret messages (chemical signals) into the bloodstream, like a distress beacon or a "We need help here!" radio broadcast.

These signals travel all the way to the lungs. When the lung's blood vessels receive these messages, they panic and change their behavior. Specifically, they start building a lot more ACKR1 on their surface.

• The Analogy: Imagine the lung's blood vessels are like a quiet suburban street. When the cancer sends its signal, it's like a loud siren going off. The streetlights (the blood vessels) suddenly turn on and start flashing, putting up "Welcome" signs (ACKR1) that weren't there before.

Act 2: The "Grease" for the Slide

The paper found that this new ACKR1 protein acts like a super-sticky glue or a magnet. Its main job is to catch neutrophils.

Neutrophils are white blood cells. Usually, they are the body's "first responders," like firefighters or police officers that rush to fight infections. However, in this specific scenario, the cancer has tricked them. The ACKR1 on the blood vessels grabs the neutrophils and pulls them out of the bloodstream and into the lung tissue.

• The Analogy: Think of the blood vessels as a highway. The ACKR1 is like a giant magnet placed on the side of the road. The neutrophils are cars driving by. The magnet yanks the cars off the highway and onto the shoulder. Once off the road, these neutrophils stop fighting the cancer and actually start helping it. They build a safe zone, clear away the body's natural defenses (like the immune system's "police"), and help the cancer cells settle in.

Act 3: The Break-in

Once the neutrophils are there, they create a cozy, safe environment (called the metastatic niche). This is the perfect spot for the cancer cells to arrive.

The researchers found that the cancer cells also prefer to land right next to these ACKR1-covered blood vessels. It's as if the cancer cells are looking for the specific address where the "Welcome Committee" (the neutrophils) is waiting.

• The Result: The cancer cells slide out of the blood, land in the lung, and start growing a new tumor.

---

The Experiment: Turning Off the "Welcome Sign"

To prove that ACKR1 was the villain, the scientists created a special group of mice where they could turn off the ACKR1 gene specifically in the blood vessels of the lungs. They left the rest of the body (including the red blood cells) alone.

• What happened?
  1. The cancer still grew in the breast (the primary tumor didn't care).
  2. The cancer cells still traveled to the lungs.
  3. BUT, without the ACKR1 "magnet," the neutrophils didn't get pulled out of the blood.
  4. Without the neutrophils to build the safe zone, the cancer cells couldn't get a foothold. They arrived, but they couldn't stay or grow.

The Takeaway: The cancer needs the lung's blood vessels to put up the "ACKR1" sign to recruit the neutrophil "helpers." If you take away that sign, the cancer can't establish a new home in the lungs.

---

Why This Matters (The "So What?")

This is a big deal for two reasons:

1. It's a New Weakness: We now know that blocking ACKR1 could stop cancer from spreading to the lungs without necessarily killing the cancer cells directly. It's like locking the front door so the burglars can't get in, rather than trying to fight them inside the house.
2. It's Specific: Since this happens mostly in the lungs during metastasis, a drug targeting this might not mess up the rest of the body's immune system (which needs neutrophils to fight real infections).

Summary in One Sentence

Breast cancer tricks the blood vessels in the lungs into putting up a "Welcome Sign" (ACKR1), which pulls in helpful neutrophils that build a safe house for the cancer to grow; if you remove that sign, the cancer can't move in.

Technical Summary

1. Problem Statement

Metastasis is the primary cause of breast cancer mortality. A critical step in this process is the formation of the premetastatic niche, where distant tissues (specifically the lung) are primed by signals from the primary tumor to support the arrival and engraftment of circulating tumor cells (CTCs).

• The Gap: While endothelial activation and neutrophil recruitment are known to be essential for niche formation, the specific molecular mechanisms driving these events remain incompletely understood.
• The Specific Question: The role of Atypical Chemokine Receptor 1 (ACKR1/DARC) in the lung endothelium during metastasis is unclear. Although ACKR1 is known to regulate neutrophil trafficking in inflammation, its contribution to cancer metastasis, specifically whether it acts via endothelial cells or red blood cells (RBCs), and how it influences tumor cell engraftment, has not been directly examined.

2. Methodology

The study employed a combination of in vivo mouse models, in vitro cell culture assays, and advanced imaging/flow cytometry techniques.

• Animal Models:

  • Global Knockout: Used Ackr1^Null mice (global deletion) to assess the overall impact of ACKR1 loss.
  • Conditional Knockout (Key Innovation): Generated a novel endothelial-specific conditional knockout (Ackr1^flox/flox; Cdh5^CreERT2, referred to as Ackr1^ECKO). This model allows for the selective ablation of ACKR1 in endothelial cells while preserving expression in RBCs, distinguishing cell-type-specific functions.
  • Tumor Models:
    • Orthotopic Implantation: Syngeneic mammary carcinoma cells (E0771.LMB, PY8119, AT3) implanted into the mammary fat pad of immunocompetent mice.
    • Spontaneous Model: MMTV-PyMT transgenic mice to mimic natural tumor progression.
    • Experimental Metastasis: Tail vein injection of tumor cells to bypass the primary tumor and test lung engraftment directly.
  • Priming Strategy: Intraperitoneal injection of Tumor Conditioned Media (TCM) to simulate tumor-secreted factors inducing the premetastatic niche without direct tumor cell contact.

• In Vitro Assays:

  • Endothelial Activation: Human Umbilical Vein Endothelial Cells (HUVECs) treated with TCM from mouse (LMB) and human (MDA-MB-231) breast cancer lines to measure ACKR1 upregulation (qPCR, flow cytometry).
  • Transendothelial Migration (TEM): 3D collagen gel assays measuring neutrophil adhesion and transmigration across HUVEC monolayers primed with TCM.

• Analytical Techniques:

  • Immunofluorescence/IHC: Staining for ACKR1, CD31 (pan-endothelial), EphB4 (venous marker), Pan-Cytokeratin (tumor cells), and Ly6G/Gr-1 (neutrophils).
  • Image Analysis: Custom QuPath macros used for blinded quantification of vessel density, cell proximity (distance to nearest vessel), and metastatic burden.
  • Flow Cytometry: Used to quantify circulating neutrophils, distinguish intravascular vs. extravascular tumor cells (using anti-MHCI antibody labeling), and measure endothelial ACKR1 surface expression.

3. Key Contributions

• Discovery of Endothelial ACKR1 Upregulation: Demonstrated that primary breast tumors induce ACKR1 expression specifically in pulmonary venules (EphB4+ vessels) as an early event in premetastatic niche formation, occurring before tumor cell seeding.
• Development of a Specific Genetic Tool: Successfully generated and validated the first endothelial-specific Ackr1 conditional knockout mouse, resolving the ambiguity of previous global knockout studies regarding whether ACKR1's role in metastasis is driven by endothelial cells or RBCs.
• Mechanistic Decoupling: Proved that endothelial ACKR1 is required for neutrophil recruitment and metastatic engraftment, but not for the initial extravasation (exit from blood) of tumor cells.

4. Key Results

• ACKR1 is Required for Lung Metastasis:

  • Global Ackr1^Null mice showed significantly reduced lung metastasis compared to Wild Type (WT), while primary tumor growth remained unaffected.
  • Endothelial-specific deletion (Ackr1^ECKO) recapitulated this phenotype, confirming that endothelial ACKR1 is the critical driver.

• Temporal and Spatial Dynamics:

  • ACKR1 upregulation in lung endothelium begins at Day 13 post-tumor implantation, preceding the detection of tumor cells in the lung (Day 28+).
  • ACKR1 expression is restricted to post-capillary venules (EphB4+).
  • Tumor-conditioned media (TCM) alone is sufficient to upregulate endothelial ACKR1, indicating a soluble factor-mediated mechanism.

• Cellular Localization:

  • Both neutrophils (Ly6G+) and disseminated tumor cells showed a ~2.8-fold enrichment within 50 µm of ACKR1-positive venules compared to ACKR1-negative vessels.

• Mechanism of Action (Neutrophils vs. Tumor Cells):

  • Tumor Extravasation: Ackr1^ECKO mice had no defect in the initial recruitment or extravasation of tumor cells from the bloodstream into the lung parenchyma.
  • Neutrophil Recruitment: Ackr1^ECKO mice exhibited a significant reduction in neutrophil infiltration into the lung metastatic niche. Circulating neutrophil levels remained normal, indicating the defect is in tissue recruitment, not production.
  • In Vitro Validation: TCM-primed HUVECs showed increased neutrophil adhesion and transmigration. This effect was dependent on ACKR1, as Ackr1^ECKO endothelial cells failed to support this enhanced migration.

5. Significance

• Novel Therapeutic Target: The study identifies endothelial ACKR1 as a critical, druggable node in the tumor-endothelial-neutrophil axis. Targeting ACKR1 could disrupt the formation of the premetastatic niche without broadly suppressing systemic immunity (since RBC ACKR1 is preserved in the conditional model).
• Clarification of ACKR1 Biology: Resolves the debate on whether ACKR1's role in metastasis is mediated by RBCs (chemokine reservoirs) or endothelial cells (chemokine presentation). The data strongly supports the endothelial presentation model for metastatic niche formation.
• Biomarker Potential: Endothelial ACKR1 upregulation in the lung vasculature could serve as an early biomarker for premetastatic niche formation, allowing for risk stratification and early intervention before overt metastasis occurs.
• Paradigm Shift: Highlights that the "niche" is actively remodeled by tumor-derived factors to recruit specific immune subsets (neutrophils) via endothelial receptors, which then facilitate tumor cell survival and outgrowth.

In conclusion, this paper establishes that breast tumors secrete factors that upregulate ACKR1 on lung venular endothelium. This upregulation creates a chemokine gradient that recruits neutrophils, which in turn create a microenvironment permissive for tumor cell engraftment and metastatic outgrowth.